187 related articles for article (PubMed ID: 36372347)
21. Agreement of Spectral-Domain OCT with Fluorescein Leakage in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
Khurana RN; Hill L; Ghanekar A; Gune S
Ophthalmol Retina; 2020 Nov; 4(11):1054-1058. PubMed ID: 32353536
[TBL] [Abstract][Full Text] [Related]
22. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
Steinle NC; Du W; Gibson A; Saroj N
Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
[TBL] [Abstract][Full Text] [Related]
23. Characterization of Drusen and Hyperreflective Foci as Biomarkers for Disease Progression in Age-Related Macular Degeneration Using Artificial Intelligence in Optical Coherence Tomography.
Waldstein SM; Vogl WD; Bogunovic H; Sadeghipour A; Riedl S; Schmidt-Erfurth U
JAMA Ophthalmol; 2020 Jul; 138(7):740-747. PubMed ID: 32379287
[TBL] [Abstract][Full Text] [Related]
24. MACULAR ATROPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Post Hoc Analysis of Patients With Pigment Epithelial Detachments.
Rebhun CB; Moreira-Neto C; Gune S; Hill L; Duker JS; Waheed NK
Retina; 2020 Feb; 40(2):266-272. PubMed ID: 31972796
[TBL] [Abstract][Full Text] [Related]
25. Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes.
Blazaki S; Blavakis E; Chlouverakis G; Bontzos G; Chatziralli I; Smoustopoulos G; Dimitriou E; Stavrakakis A; Kabanarou S; Xirou T; Vavvas DG; Tsilimbaris MK
Graefes Arch Clin Exp Ophthalmol; 2023 Dec; 261(12):3425-3436. PubMed ID: 37566302
[TBL] [Abstract][Full Text] [Related]
26. Macular atrophy development in neovascular age-related macular degeneration during first year of treatment: Incidence and risk factors.
Oliveira MA; Farinha C; Rodrigues TM; Martins A; Cachulo MDL; Marques JP; Pires I; Silva R
Eur J Ophthalmol; 2021 Mar; 31(2):521-528. PubMed ID: 32103681
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and Progression of Macular Atrophy in Eyes with Neovascular Age-Related Macular Degeneration in the Phase 2 Ladder Trial of the Port Delivery System with Ranibizumab.
Jaffe GJ; Cameron B; Kardatzke D; Ives J; Barteselli G; Gune S
Ophthalmol Retina; 2022 Sep; 6(9):786-795. PubMed ID: 35427803
[TBL] [Abstract][Full Text] [Related]
28. Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration.
Lee JY; Chung H; Kim HC
Korean J Ophthalmol; 2016 Feb; 30(1):17-24. PubMed ID: 26865799
[TBL] [Abstract][Full Text] [Related]
29. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
[TBL] [Abstract][Full Text] [Related]
30. Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial.
Fan W; Abdelfattah NS; Uji A; Lei J; Ip M; Sadda SR; Wykoff CC;
Graefes Arch Clin Exp Ophthalmol; 2018 Mar; 256(3):511-518. PubMed ID: 29374796
[TBL] [Abstract][Full Text] [Related]
31. Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration.
Zarubina AV; Gal-Or O; Huisingh CE; Owsley C; Freund KB
Invest Ophthalmol Vis Sci; 2017 Dec; 58(14):6038-6045. PubMed ID: 29196768
[TBL] [Abstract][Full Text] [Related]
32. Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Finn AP; Pistilli M; Tai V; Daniel E; Ying GS; Maguire MG; Grunwald JE; Martin DF; Jaffe GJ; Toth CA;
Am J Ophthalmol; 2021 Mar; 223():338-347. PubMed ID: 33221285
[TBL] [Abstract][Full Text] [Related]
33. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.
Munk MR; Ceklic L; Ebneter A; Huf W; Wolf S; Zinkernagel MS
Acta Ophthalmol; 2016 Dec; 94(8):e757-e764. PubMed ID: 27417506
[TBL] [Abstract][Full Text] [Related]
34. Correlation between neovascular lesion type and clinical characteristics of nonneovascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration.
Marsiglia M; Boddu S; Chen CY; Jung JJ; Mrejen S; Gallego-Pinazo R; Freund KB
Retina; 2015 May; 35(5):966-74. PubMed ID: 25627089
[TBL] [Abstract][Full Text] [Related]
35. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).
Bhisitkul RB; Desai SJ; Boyer DS; Sadda SR; Zhang K
Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339
[TBL] [Abstract][Full Text] [Related]
36. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG;
Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282
[TBL] [Abstract][Full Text] [Related]
37. Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye.
Abdelfattah NS; Zhang H; Boyer DS; Rosenfeld PJ; Feuer WJ; Gregori G; Sadda SR
Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1839-46. PubMed ID: 27082298
[TBL] [Abstract][Full Text] [Related]
38. Imaging, Genetic, and Demographic Factors Associated With Conversion to Neovascular Age-Related Macular Degeneration: Secondary Analysis of a Randomized Clinical Trial.
Hallak JA; de Sisternes L; Osborne A; Yaspan B; Rubin DL; Leng T
JAMA Ophthalmol; 2019 Jul; 137(7):738-744. PubMed ID: 31021381
[TBL] [Abstract][Full Text] [Related]
39. Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen.
Mantel I; Zola M; De Massougnes S; Dirani A; Bergin C
Br J Ophthalmol; 2019 Jul; 103(7):900-905. PubMed ID: 30166328
[TBL] [Abstract][Full Text] [Related]
40. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
